Abstract
Diabetic vascular complication is a leading cause of acquired blindness, end-stage renal failure, a variety of neuropathies and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. Chronic hyperglycemia is essentially involved in the development and progression of diabetic micro- and macroangiopathy. Among various metabolic derangements implicated in the pathogenesis of diabetic vascular complication, advanced glycation end product (AGE) hypothesis is most compatible with the theory of hyperglycemic memory. In this review, we discuss the molecular mechanisms of diabetic vascular complication, specially focusing on AGEs and their receptor (RAGE) system. Several types of AGE inhibitors and their therapeutic implications in this devastating disorder are also discussed here.
Keywords: diabetic vascular complications, atherosclerosis, ages, oxidative stress, rage, renin-angiotensin system, insulin resistance, pigment epithelium-derived factor
Current Diabetes Reviews
Title: Advanced Glycation End Products (AGEs) and Diabetic Vascular Complications
Volume: 1 Issue: 1
Author(s): Sho-ichi Yamagishi, Kazuo Nakamura and Tsutomu Imaizumi
Affiliation:
Keywords: diabetic vascular complications, atherosclerosis, ages, oxidative stress, rage, renin-angiotensin system, insulin resistance, pigment epithelium-derived factor
Abstract: Diabetic vascular complication is a leading cause of acquired blindness, end-stage renal failure, a variety of neuropathies and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. Chronic hyperglycemia is essentially involved in the development and progression of diabetic micro- and macroangiopathy. Among various metabolic derangements implicated in the pathogenesis of diabetic vascular complication, advanced glycation end product (AGE) hypothesis is most compatible with the theory of hyperglycemic memory. In this review, we discuss the molecular mechanisms of diabetic vascular complication, specially focusing on AGEs and their receptor (RAGE) system. Several types of AGE inhibitors and their therapeutic implications in this devastating disorder are also discussed here.
Export Options
About this article
Cite this article as:
Yamagishi Sho-ichi, Nakamura Kazuo and Imaizumi Tsutomu, Advanced Glycation End Products (AGEs) and Diabetic Vascular Complications, Current Diabetes Reviews 2005; 1 (1) . https://dx.doi.org/10.2174/1573399052952631
DOI https://dx.doi.org/10.2174/1573399052952631 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Age-Related Sleep Changes and its Implication in Neurodegenerative Diseases
Current Aging Science Therapeutic Implications of mTOR Inhibitors in the Treatment of Gastric Cancer
Current Cancer Drug Targets The Inflammation Paradigm and Coronary Artery Disease: What Celsus, Virchow and Gene Knock Outs Have Taught Us
Cardiovascular & Hematological Disorders-Drug Targets Knowledge, Attitude and Practice on Disposal of Sharps Waste at Home Among Patients with Diabetes and their Caregivers
Current Diabetes Reviews Classic Histamine H1 Receptor Antagonists: A Critical Review of their Metabolic and Pharmacokinetic Fate from a Birds Eye View
Current Drug Metabolism A Perspective on the Current Strategies for the Treatment of Obesity
Current Drug Targets - CNS & Neurological Disorders Optical Diagnosis of Head and Neck Cancers (Review)
Reviews on Recent Clinical Trials Therapeutic Potentials of Triterpenes in Diabetes and its Associated Complications
Current Topics in Medicinal Chemistry Understanding Cancer Drug Resistance by Developing and Studying Resistant Cell Line Models
Current Cancer Drug Targets Neuro-Psychiatric Alterations in Patients with Diabetic Foot Syndrome
CNS & Neurological Disorders - Drug Targets Clinical Resolution of Type 2 Diabetes with Reduction in Body Mass Index Using Meal Replacement Based Weight Loss
Vascular Disease Prevention (Discontinued) HIV Management: New Approaches
Current Drug Therapy Difluorinated Curcumin: A Promising Curcumin Analogue with Improved Anti-Tumor Activity and Pharmacokinetic Profile
Current Pharmaceutical Design Neuro-Transmitters in the Central Nervous System & their Implication in Learning and Memory Processes
Current Medicinal Chemistry Experimental Models for Aging and their Potential for Novel Drug Discovery
Current Neuropharmacology Plasma Metabolic Profiling of Mild Cognitive Impairment and Alzheimer's Disease Using Liquid Chromatography/Mass Spectrometry
Central Nervous System Agents in Medicinal Chemistry Uridine Function in the Central Nervous System
Current Topics in Medicinal Chemistry Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies
Current Diabetes Reviews Noncoding RNAs and Intracerebral Hemorrhage
CNS & Neurological Disorders - Drug Targets The Role of Chemokines, Cytokines and Adhesion Molecules in Stem Cell Trafficking and Homing
Current Pharmaceutical Design